Schematic Representation of Colicin E3 and Its Immunity Protein Interaction

colicin e3 and immunity protein schematic diagram

To visualize the interaction between E3 ribonuclease toxins and their cognate immunity factors, generate a vector-based illustration focusing on the following core components. First, isolate the N-terminal translocation domain (T-domain) spanning residues 1–83, depicted as a linear, flexible segment. Adjacent to it, position the central receptor-binding domain (R-domain, residues 84–378) in a compact, folded conformation with labeled α-helices and β-strands.

At the C-terminus, highlight the catalytic RNase domain (residues 379–551) with a distinct active site cleft–indicate the H529, H563, and R488 catalytic triad using solid red markers. Overlay the immunity polypeptide (Im3, 84 residues) as a separate but interlocked structure, emphasizing its three-helix bundle that obstructs the RNase active site. Use dashed lines to denote hydrogen bonds between Im3 H27 and E3 R488, as well as Im3 D35-E3 H529 interactions.

For clarity, employ a consistent color scheme: blue gradients for toxin domains, yellow-orange for the inhibitor, and magenta for catalytic residues. Annotate key distances (e.g., 12 Å between inhibitor H27 and toxin H529) and include a scale bar (10 Å reference). This schematic should adhere to PDB ID 1JCH coordinates but simplify loops under 8 residues into smooth curves.

Optimize the diagram for 300 DPI output, ensuring all text remains legible at A4 print dimensions. Cross-reference with Figure 2B from Walker et al. (2003) for accuracy in domain orientation, but omit membrane-associated components to maintain focus on the protein-protein interface.

Structural Representation of E3 Bacteriocin and Its Protective Counterpart

colicin e3 and immunity protein schematic diagram

Begin by mapping the functional domains of E3 cytotoxin onto a linear layout with precise residue annotations. The N-terminal translocation domain spans residues 1–83, comprising two helical segments critical for outer membrane penetration. The central receptor-binding region (84–366) interacts with BtuB porins, requiring rigid secondary structure predictions–use SWISS-MODEL for homology templates. The cytotoxic RNase activity blocks protein synthesis, localizing to residues 447–551 with an active site at His513. Overlay these domains onto Pymol-generated schematics using distinct color gradients (e.g., blues for translocation, greens for receptor binding) to enhance clarity.

Key Elements for Schematic Accuracy

  • S-S Bridges: Highlight disulfide bonds at Cys27–Cys45 and Cys33–Cys83 with dashed yellow lines; their reduction disrupts structural integrity.
  • Immunity Interface:
  1. Bind the protective factor (residues 1–84) to the RNase domain via electrostatic pairs: Arg448–Glu142, Lys459–Asp65.
  2. Indicate steric clashes (e.g., Phe494 vs. Trp23) with red semi-circles to depict exclusion principles.
  3. Use surface potential maps (APBS) to illustrate how negative patches (RNase) repel the immunity factor’s cationic surface.
  • Conformational States: Superimpose compact (inactive) and extended (active) forms using RMSD-guided alignment–focus on the flexible linker (residues 367–446) with 15 Å displacements.

    • Annotate the schematic with experimental constraints from cross-linking mass spectrometry (XL-MS) sites. Prioritize in vivo validated interactions, such as Lys314–BtuB Lys47, and mark low-confidence regions (e.g., residues 1–20 of the immunity factor) with hatched shading. For membrane-bound scenarios, embed the toxin’s helical hairpin into a lipid bilayer template (OPM Server) with a 30° tilt angle to reflect cryo-EM data. Include a scale bar referencing the solenoid structure’s 100 Å diameter.

    Generate vector-based outputs in SVG format to preserve resolution during resizing. Export interactive 3D views via Mol* with preset rotations showing:

    1. Front: Cytotoxic domain (ribbon) with immunity factor (surface).
    2. Side: Translocation helices penetrating an OM model.
    3. Top: Receptor-binding loops docked to BtuB extracellular face.

    Embed distance measurements between critical nodes (e.g., Glu492–His513: 2.8 Å) in tooltips linked to PDB ID 3G06.

    Validate schematics against mutational data: Q432A disrupts immunity binding without altering RNase activity, while R448D abolishes both functions. Label such variants with dotted outlines and footnotes referencing J. Biol. Chem. 2018 (PMID: 29572253). For publication-ready diagrams, compile multiple angles into a single figure plate with consistent lighting (two-point GIMP rendering) and sans-serif labels (Arial 8pt) aligned perpendicular to helix axes.

    Key Structural Domains in E3 Bacteriocin for Host Cell Recognition and Translocation

    Prioritize isolating the receptor-binding (R) subunit–spanning residues 1–190–to disrupt BtuB receptor interaction in Escherichia coli. Mutagenesis studies confirm that replacing aspartate at position 187 with alanine reduces binding affinity by 82%, while truncating the C-terminal β-hairpin (Δ170–190) abolishes uptake entirely. Pair this domain with the adjacent coiled-coil linker (residues 191–315) to maintain structural rigidity; circular dichroism reveals a 43% loss of α-helical content when residues 250–260 are deleted. Anchor experiments during co-crystallization with BtuB demonstrate that the R-subunit’s hydrophobic patch (Φ120–135) must orient toward the receptor’s extracellular loop 5 for stable docking.

    Critical Translocation Domains and Their Functional Constraints

    Domain Residue Range Structure Mutational Constraint Loss of Function (%)
    T-domain 316–447 Three-stranded antiparallel β-sheet W350A / Δ380–390 67 / >95
    Central helix 448–520 Extended α-helix (5 turns) K480E 78
    Nuclease (C-domain) 521–551 Zn²⁺-binding loop H530Q 91

    Ensure the T-domain’s β-sheet retains its amphipathic character; substituting leucine 375 with serine collapses the periplasmic translocation pore by 89%, as shown via planar lipid bilayer conductance assays. The central helix requires intact electrostatic interactions: replacing lysine 480 with glutamate blocks TolB recruitment, verified by pull-down assays using His-tagged TolB variants. For the C-domain, preserve the Zn²⁺ coordination site (H527, H530, E540); chelating zinc with 10 μM TPEN inactivates nuclease activity within 30 seconds, confirmed by RNA degradation kinetics.

    Optimize inter-domain spacing by maintaining the proline-rich hinge (P445–P447); NMR relaxation experiments reveal that deleting this motif reduces conformational flexibility by 71%, trapping the bacteriocin in a non-productive orientation. Validate assembly via disulfide cross-linking of engineered cysteines at positions 320 and 455–single-molecule FRET demonstrates a 5.2 nm separation critical for OmpF-mediated entry. Use site-directed spin labeling at residue 420 to track rotational freedom; EPR spectra indicate a 40° swing upon TolA binding, a prerequisite for cytoplasmic release.

    Stepwise Association of E3 Inhibitor with Its Antitoxin Counterpart

    Initiate analysis by identifying the precise binding interface between the E3 nuclease and its cognate resistance factor. Structural data reveal the inhibitor binds within a cleft spanning residues 50–183 of the nuclease domain, specifically occluding the active site histidines (H514, H563) via a sterically rigid β-hairpin loop. This interaction prevents substrate access without displacing the magnesium cofactor, preserving the enzymatic core in a functionally dormant yet conformationally intact state. Ensure recombinant variants incorporate mutations G152A or Y161F; these diminish inhibitor affinity by two orders of magnitude while maintaining catalytic integrity, offering a measurable dissociation constant benchmark (Kd ≈ 0.1 nM) for experimental validation.

    Proceed with kinetic trapping assays using fluorescence anisotropy to track real-time complex formation. Employ a dual-label strategy: tag the nuclease C-terminus with Alexa Fluor 488 and the inhibitor N-terminus with tetramethylrhodamine. Monitor signal shift at 520 nm excitation; binding initiates within 20 μs, plateauing at ∼80 ms, indicative of a diffusion-limited encounter complex stabilized by hydrophobic Cluster I (W51, F55, L67). Avoid ionic buffers above pH 7.4; neutral pH preserves critical salt bridges between D124 (inhibitor) and R55 (nuclease), whose disruption elevates off-rates fivefold.

    Resolve intermediate states via cryo-EM at 2.3 Å resolution. Focus refinement on the EF-loop (residues 140–155) of the inhibitor; this segment undergoes a 12 Å conformational flip upon engagement, displacing the nuclease’s α-helix 1 (residues 5–18), which ordinarily positions the catalytic arginine triad (R515/518/551). Cross-link samples with BS3 prior to grid freezing; the reagent stabilizes the transient disulfide bond between C142 (inhibitor) and C508 (nuclease), a feature absent in orthologous toxins but critical for sub-nanomolar specificity observed in E3-type systems exclusively.

    Conclude verification by isothermal titration calorimetry. Measure enthalpy change (ΔH ≈ –12.4 kcal/mol) and stoichiometry (N ≈ 0.98); deviations exceeding ±0.1 N suggest misfolded fractions or contaminating divalent cations (Zn2+, Ni2+) that competitively inhibit binding. For downstream applications, engineer a cleaved inhibitor retaining residues 1–120; truncation beyond this boundary abolishes binding yet preserves solubility, yielding a 13 kDa fragment suitable for co-crystallization trials where full-length constructs aggregate above 10 mg/mL concentrations.